Prime Medicine (PRME) Competitors $4.10 +0.30 (+7.89%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$4.14 +0.04 (+0.98%) As of 07/8/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRME vs. CVAC, CALT, GPCR, AUPH, NAGE, AMPH, DYN, PAHC, BGM, and ABCLShould you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), Aurinia Pharmaceuticals (AUPH), Niagen Bioscience (NAGE), Amphastar Pharmaceuticals (AMPH), Dyne Therapeutics (DYN), Phibro Animal Health (PAHC), BGM Group (BGM), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry. Prime Medicine vs. Its Competitors CureVac Calliditas Therapeutics AB (publ) Structure Therapeutics Aurinia Pharmaceuticals Niagen Bioscience Amphastar Pharmaceuticals Dyne Therapeutics Phibro Animal Health BGM Group AbCellera Biologics CureVac (NASDAQ:CVAC) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends. Which has better earnings and valuation, CVAC or PRME? CureVac has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCureVac$579.18M2.10$175.50M$0.925.89Prime Medicine$3.85M139.97-$198.13M-$1.61-2.55 Do insiders and institutionals have more ownership in CVAC or PRME? 17.3% of CureVac shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 22.9% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is CVAC or PRME more profitable? CureVac has a net margin of 35.44% compared to Prime Medicine's net margin of 0.00%. CureVac's return on equity of 30.89% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets CureVac35.44% 30.89% 25.54% Prime Medicine N/A -107.87%-74.97% Which has more risk & volatility, CVAC or PRME? CureVac has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.33, suggesting that its stock price is 133% more volatile than the S&P 500. Do analysts recommend CVAC or PRME? CureVac currently has a consensus price target of $6.83, indicating a potential upside of 26.08%. Prime Medicine has a consensus price target of $10.08, indicating a potential upside of 145.93%. Given Prime Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Prime Medicine is more favorable than CureVac.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 Does the media prefer CVAC or PRME? In the previous week, Prime Medicine had 8 more articles in the media than CureVac. MarketBeat recorded 9 mentions for Prime Medicine and 1 mentions for CureVac. Prime Medicine's average media sentiment score of 0.89 beat CureVac's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CureVac 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPrime Medicine beats CureVac on 9 of the 17 factors compared between the two stocks. Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRME vs. The Competition Export to ExcelMetricPrime MedicineBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$538.31M$207.74M$5.47B$20.52BDividend YieldN/AN/A5.25%3.76%P/E Ratio-2.00N/A27.0027.79Price / Sales139.97259.79435.7540.48Price / CashN/A22.4436.8222.26Price / Book2.995.707.984.58Net Income-$198.13M-$96.61M$3.16B$982.91M7 Day Performance33.55%4.68%2.40%0.41%1 Month Performance145.51%0.60%2.19%3.59%1 Year Performance-27.05%9.39%33.82%14.47% Prime Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRMEPrime Medicine4.0479 of 5 stars$4.10+7.9%$10.08+145.9%-25.3%$538.31M$3.85M-2.00234News CoverageOptions VolumeHigh Trading VolumeCVACCureVac4.4998 of 5 stars$5.43+0.9%$6.83+25.8%+73.2%$1.22B$579.18M5.90880CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180GPCRStructure Therapeutics2.6717 of 5 stars$20.74-1.6%$76.17+267.2%-49.7%$1.19BN/A-23.84136Positive NewsAUPHAurinia Pharmaceuticals2.5572 of 5 stars$8.47-2.0%$11.50+35.8%+34.8%$1.14B$235.13M30.25300NAGENiagen Bioscience1.2984 of 5 stars$14.41+1.3%$19.50+35.3%N/A$1.14B$107.93M84.76120AMPHAmphastar Pharmaceuticals4.4152 of 5 stars$22.96-0.5%$32.33+40.8%-39.5%$1.08B$730.66M8.322,028DYNDyne Therapeutics3.6401 of 5 stars$9.52-0.5%$41.13+332.0%-75.0%$1.08BN/A-2.65100PAHCPhibro Animal Health3.673 of 5 stars$25.54-0.5%$21.80-14.6%+71.9%$1.04B$1.02B32.741,940News CoverageAnalyst UpgradeBGMBGM GroupN/A$10.59-11.5%N/AN/A$1.03B$25.10M0.00298News CoverageAnalyst DowngradeABCLAbCellera Biologics2.5473 of 5 stars$3.43-5.0%$8.33+143.0%+41.5%$1.02B$28.83M-6.12500News CoverageAnalyst ForecastHigh Trading Volume Related Companies and Tools Related Companies CureVac Alternatives Calliditas Therapeutics AB (publ) Alternatives Structure Therapeutics Alternatives Aurinia Pharmaceuticals Alternatives Niagen Bioscience Alternatives Amphastar Pharmaceuticals Alternatives Dyne Therapeutics Alternatives Phibro Animal Health Alternatives BGM Group Alternatives AbCellera Biologics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PRME) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
